Related Experiment Video

Updated: May 27, 2026

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells

Lars Anders1, Nan Ke, Per Hydbring

  • 1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. lars.anders.hms@gmail.com

Cancer Cell
|November 19, 2011
PubMed

Insights

Cyclin-dependent kinases 4 and 6 (CDK4/6) activate the FOXM1 transcription factor, promoting cancer cell survival and proliferation. Inhibiting CDK4/6 halts these processes, offering a potential therapeutic strategy for cancers like melanoma.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Cell Cycle Regulation

Background:

  • Cyclin D-dependent kinases (CDK4 and CDK6) regulate cell cycle entry and are frequently overactive in human cancers.
  • The precise mechanisms by which CDK4/6 contribute to tumorigenesis are not fully elucidated due to a limited understanding of their substrates.

Purpose of the Study:

  • To systematically identify substrates of cyclin D1-CDK4 and cyclin D3-CDK6 complexes.
  • To investigate the role of identified substrates in cancer progression and the response to CDK4/6 inhibition.

Main Methods:

  • Systematic screening for phosphorylation targets of cyclin D1-CDK4 and cyclin D3-CDK6.
  • Functional assays to assess the impact of CDK4/6-mediated phosphorylation on target proteins and cellular processes.

Main Results:

  • The Forkhead Box M1 (FOXM1) transcription factor was identified as a critical, common phosphorylation target of CDK4/6.
  • CDK4/6 stabilize and activate FOXM1, leading to sustained expression of G1/S phase genes.
  • FOXM1 activation by CDK4/6 suppresses reactive oxygen species (ROS) and prevents cancer cell senescence.
  • Melanoma cells exhibit a strong dependence on CDK4/6 for senescence suppression, making them sensitive to CDK4/6 inhibitors.

Conclusions:

  • FOXM1 is a key downstream effector of CDK4/6 signaling in cancer.
  • CDK4/6-FOXM1 axis plays a crucial role in maintaining cancer cell proliferation and survival by suppressing senescence.
  • Targeting CDK4/6 offers a promising therapeutic avenue, particularly for cancers like melanoma that rely heavily on this pathway for senescence evasion.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.